Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

Cutting Edge: Chromatin Remodeling as a Molecular Basis for the Enhanced Functionality of Memory CD8 T Cells

(2014) J. K. Northrop et al.   JOURNAL OF IMMUNOLOGY

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells

(2012) Ke Gong et al.   BIOCHEMICAL JOURNAL

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine

(2012) Seth M. Pollack et al.   PLoS One

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia

(2011) Djordje Atanackovic et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine

(2011) Mengyong Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

(2011) C. R. Cruz et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression

(2011) Lucas E. Rossi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo

(2011) Brian R. Rosborough et al.   JOURNAL OF LEUKOCYTE BIOLOGY

A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells

(2010) Lin Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy

(2010) Stacey N Akers et al.   Future Oncology

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells

(2010) W Song et al.   LEUKEMIA

Functional Anatomy of T Cell Activation and Synapse Formation

(2009) David R. Fooksman et al.   Annual Review of Immunology

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

(2009) J. A. Dubovsky et al.   CLINICAL CANCER RESEARCH

Gene Regulation and Chromatin Remodeling by IL-12 and Type I IFN in Programming for CD8 T Cell Effector Function and Memory

(2009) P. Agarwal et al.   JOURNAL OF IMMUNOLOGY

Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia

(2008) Christina A. Ortmann et al.   ANNALS OF HEMATOLOGY

Epigenetics, DNA Methylation, and Chromatin Modifying Drugs

(2008) Moshe Szyf   Annual Review of Pharmacology and Toxicology

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

(2008) K. Rezvani et al.   BLOOD

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

(2008) C. Santamaria et al.   HAEMATOLOGICA

The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

(2008) Atsushi Natsume et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2in vitroandin vivo

(2008) Nicolas Tajeddine et al.   LEUKEMIA & LYMPHOMA

Liver stroma enhances activation of TLR3-triggered NK cells through fibronectin

(2008) Sheng Xia et al.   MOLECULAR IMMUNOLOGY